Acadia Pharmaceuticals (ACAD) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Acadia Pharmaceuticals | 3.69 Bn | 2.84 Bn | 243.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.82% |
| Dec 31, 2025 | -12.33% |
| Sep 30, 2025 | 38.05% |
| Jun 30, 2025 | 29.19% |
| Mar 31, 2025 | 19.21% |
| Dec 31, 2024 | 27.24% |
| Sep 30, 2024 | 39.79% |
| Jun 30, 2024 | 21.53% |
| Mar 31, 2024 | 19.60% |
| Dec 31, 2023 | 32.96% |
| Sep 30, 2023 | -6.37% |
| Jun 30, 2023 | 17.08% |
| Mar 31, 2023 | 17.06% |
| Dec 31, 2022 | 4.42% |
| Sep 30, 2022 | 58.41% |
| Jun 30, 2022 | 26.00% |
| Mar 31, 2022 | -1.44% |
| Dec 31, 2021 | 17.75% |
| Sep 30, 2021 | 19.26% |
| Jun 30, 2021 | 15.04% |
| Mar 31, 2021 | -8.13% |
| Dec 31, 2020 | 3.38% |
| Sep 30, 2020 | 5.21% |
| Jun 30, 2020 | -5.44% |
| Mar 31, 2020 | -13.65% |
| Dec 31, 2019 | -10.82% |
| Sep 30, 2019 | -1.51% |
| Jun 30, 2019 | -17.76% |
| Mar 31, 2019 | -35.58% |
| Dec 31, 2018 | -30.68% |
| Sep 30, 2018 | -34.35% |
| Jun 30, 2018 | -49.30% |
| Mar 31, 2018 | -47.35% |
| Dec 31, 2017 | -36.56% |
| Sep 30, 2017 | -62.51% |
| Jun 30, 2017 | -65.91% |
| Mar 31, 2017 | -68.56% |
| Dec 31, 2016 | -63.01% |
| Sep 30, 2016 | -64.16% |
| Jun 30, 2016 | -61.12% |
| Mar 31, 2016 | -51.99% |
| Dec 31, 2015 | -57.22% |
| Sep 30, 2015 | -66.26% |